Renal Clinical Trials in New York, New York
50 recruitingNew York, New York
Showing 1–20 of 50 trials
Recruiting
Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled31 locationsNCT06465069
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Project: Every Child for Younger Patients With Cancer
Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+7 more
NRG Oncology269 enrolled263 locationsNCT06500455
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Breast CancerOvarian CancerProstate Cancer+6 more
Nammi Therapeutics Inc100 enrolled10 locationsNCT06582017
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb949 enrolled48 locationsNCT04895709
Recruiting
Not Applicable
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Pancreatic CancerSarcomaMelanoma+12 more
Memorial Sloan Kettering Cancer Center26 enrolled7 locationsNCT05837767
Recruiting
Phase 1Phase 2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled8 locationsNCT04977453
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Xencor, Inc.307 enrolled23 locationsNCT05433142
Recruiting
Phase 2
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center10 enrolled7 locationsNCT06699602
Recruiting
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Colon CancerMultiple MyelomaLymphoma+2 more
Memorial Sloan Kettering Cancer Center500 enrolled6 locationsNCT00582621
Recruiting
Phase 1
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Renal Cell Carcinoma
HiberCell, Inc.80 enrolled20 locationsNCT06234605
Recruiting
Phase 1Phase 2
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Metastatic Castration-resistant Prostate Cancer (mCRPC)Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals345 enrolled21 locationsNCT03972657
Recruiting
Phase 1
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Triple-Negative Breast CancerColorectal CarcinomaNon-small Cell Lung Cancer+4 more
Janux Therapeutics130 enrolled18 locationsNCT05783622
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Not Applicable
Advanced Diffusion Imaging in Renal Cancer Patients
Renal Cancer
NYU Langone Health90 enrolled1 locationNCT06116253
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
HER2-negative Breast CancerAdvanced Solid TumorMetastatic Solid Tumor+6 more
GI Innovation, Inc.358 enrolled11 locationsNCT05824975